Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Alopecia Areata: early-phase trial registry

15 of 27 indexed Alopecia Areata trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #598 of 28,707 conditions by registered trial count.

27 US clinical trials · 15 currently recruiting · #598 of 28,707 conditions by registered trial count

Alopecia Areata: 27 US clinical trials tracked, 15 recruiting.

Alopecia Areata is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 3 of these trials.

Enrollment posture brief

Registry condition alopecia-areata

OPEN 15 | RECR 56% | LATE 5 | EARLY 15 | RANK #598 | SPON 3

Nearest open-share peer: Acute Lymphoblastic Leukemia, Pediatric (56% recruiting · 9 trials)

Alopecia Areata (this)56%Acute Ischemic Stroke44.4%Anatomic Stage IIIC Breast C33.3%Adenocarcinoma25.9%Acne22.2%
Open-enrollment share among volume-matched conditions near Alopecia Areata

Alopecia Areata lists 15 open slots (56% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Alopecia Areata on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Alopecia Areata is recruiting above its size-band peers.

    15 of 27 indexed trials (55.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Alopecia Areata trials is spread across many organizations.

    Pfizer accounts for 3 of 27 trials (11.1%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Typical Alopecia Areata enrolment sits around 94 participants.

    Median target enrolment is 94 among the 27 trials that report a genuine target (sentinel values excluded). 14 of those (51.9%) plan for fewer than 100 participants.

  4. Alopecia Areata research is mostly interventional.

    20 interventional and 7 observational studies make up this index (74.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 213Phase 34Phase 41

Open and recent trials

27 total, page 1 of 1

RECRUITING 20,000 participants

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sanguine Biosciences

NCT05635266

RECRUITING 5,000 participants

CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry

CorEvitas

NCT05745389

RECRUITING 1,500 participants

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

CorEvitas

NCT06562270

RECRUITING Phase 3 1,500 participants

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

AbbVie

NCT06012240

RECRUITING 850 participants

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

Pfizer

NCT06531109

RECRUITING Phase 3 550 participants

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

Pfizer

NCT06873945

RECRUITING Phase 3 355 participants

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Sun Pharmaceutical Industries

NCT07133308

RECRUITING Phase 2 136 participants

A Study of LAD603 in Adults With Alopecia Areata

Almirall, S.A.

NCT07311564

RECRUITING Phase 1 80 participants

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Dren Bio

NCT06602232

RECRUITING Phase 2 76 participants

Dupilumab in the Treatment of Pediatric Alopecia Areata

Icahn School of Medicine at Mount Sinai

NCT05866562

RECRUITING Phase 2 70 participants

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05398809

RECRUITING Phase 2 68 participants

Regeneron AA Multicenter (Dupilumab)

Emma Guttman

NCT05551793

RECRUITING Phase 2 56 participants

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

Icahn School of Medicine at Mount Sinai

NCT07242638

RECRUITING Phase 2 40 participants

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

University of Minnesota

NCT06747611

RECRUITING Early Phase 1 12 participants

Intralesional Cyclosporine for Alopecia Areata

University of California, Davis

NCT07029204

ACTIVE NOT RECRUITING 15,000 participants

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Target PharmaSolutions

NCT03661866

ACTIVE NOT RECRUITING 3,100 participants

Alopecia Areata Registry

M.D. Anderson Cancer Center

NCT00069589

ACTIVE NOT RECRUITING Phase 3 1,052 participants

Long-Term PF-06651600 for the Treatment of Alopecia Areata

Pfizer

NCT04006457

ACTIVE NOT RECRUITING Phase 2 1,000 participants

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Sun Pharmaceutical Industries

NCT03898479

ACTIVE NOT RECRUITING Phase 2 166 participants

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Sanofi

NCT06444451

ACTIVE NOT RECRUITING Phase 2 94 participants

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Nektar Therapeutics

NCT06340360

ACTIVE NOT RECRUITING Phase 2 75 participants

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Q32 Bio

NCT06018428

COMPLETED Phase 4 20 participants

Aldara for the Treatment of Extensive Alopecia Areata

Hordinsky, Maria K., MD

NCT00177021

COMPLETED Phase 2 12 participants

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Columbia University

NCT01950780

COMPLETED Phase 2 12 participants

Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

Columbia University

NCT02299297

COMPLETED 10 participants

A Study of Vitamin D in Subjects With Alopecia Areata

Avera McKennan Hospital & University Health Center

NCT01328678

COMPLETED Phase 2 1 participants

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

Aclaris Therapeutics

NCT03551821

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 13
Phase 3 4
Phase 4 1

Named interventions

Most-linked intervention names on Alopecia Areata records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
6 trials
Ruxolitinib Drug
2 trials
Dupilumab Drug
2 trials
Aldara Cream 5% Drug
1 trials
ATI-50002 Drug
1 trials
CTP-543 Drug
1 trials
bempikibart (ADX-914) Drug
1 trials
Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine Biological
1 trials

US sites by state

Facility locations filed on Alopecia Areata trials. A trial with sites in several states counts in each.

California 15 trials
Florida 11 trials
New York 9 trials
Massachusetts 7 trials
Indiana 6 trials
Arkansas 6 trials
Alabama 6 trials
Minnesota 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Alopecia Areata page

27 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 15 Alopecia Areata trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Pfizer sponsors the most Alopecia Areata trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alopecia Areata condition card totals 27 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.